

The **Multiplier** Effect

MAXIMIZING VALUE

The Biocon Group logo, featuring the same stylized blue icon as the Biocon logo to the left of the words "Biocon Group" in a bold, blue sans-serif font.

Corporate Presentation

**Biocon Group is a global
biopharmaceuticals frontrunner
committed to provide equitable access
to high-quality, life-saving medicines
to millions of patients worldwide**





VISION

To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe.



VALUES

- Value Creation through Innovation & Differentiation
- Quality through Compliance & Best Practices
- Integrity & Ethical Behavior
- Collaboration, Team-Work & Mutual Respect
- Performance driven Work Culture

Biocon Group At A Glance



16,300+
Total Employees¹



120+
Countries where Biocon
products are available



1,700+
Patents¹



8
Manufacturing sites



100+
cGMP approvals
from international
regulatory agencies





14 of Top 20
Pharma companies served
by service portfolio of
Syngene¹

¹. FY24



Our Business Evolution Over The Years



An Enzymes Company	Transforming Into a Biopharma Company	Building the Base Business and Expertise in Biologics	Building Scale for Global Impact	Poised for Global Impact: Biosimilars, Generics, Research Services	Working on Becoming a Global Leader
	Successful IPO, Biocon listed in India (2004)	Enzymes Business Divested (2007)	Generic Formulations Business set up (2013)	Establishes Biocon Biologics Ltd (BBL) as independent entity (2019)	Biocon crosses USD 1 Bn revenue mark in FY23
			Syngene goes public in India (2015)	Biocon Biologics acquires Viatrix' global biosimilars business to emerge as a fully integrated, global biosimilars company (2022)	Biocon Biologics integrates acquired business; crosses USD 1Bn revenue milestone in FY24

NOTE:
1 USD = 65 INR except FY2019 and FY2023 ;
FY2019: 1 USD = 69 INR | FY23: 1 USD = 82 INR

Our Global Presence



- Office
- Manufacturing
- Research

Leading Global, Diversified Biopharmaceuticals Group



Driving Greater Health Equity Through Affordable Healthcare Products & Services

Differentiated and Well-Balanced Portfolio of Generics, Biosimilars, Novel Biologics and Research Services



Ensuring Access
through Quality,
Affordability, Reliability



Pushing Scientific
Boundaries to Deliver
Impactful Innovations




Transforming Healthcare.
Transforming Lives.



Putting Science to
Work

Generics Business

APIs



Leadership in fermentation-based APIs – Immunosuppressants, statins, anti-infectives



- **50+** APIs in portfolio
- Serving **750+** API customers
- Supplying to **100+** countries



Expanding portfolio to include oncology-based **HPAPIs** and peptides, particularly **GLP-1s**

FORMULATIONS



Vertically integrated player with **60+** generic formulations in portfolio



- **17** products launched in U.S.
- **3** launched in Europe
- Few in Emerging Markets



Portfolio addresses 10 of the Top 50 drugs in the U.S. market

State-of-the-Art R&D and Manufacturing Capabilities



- **R&D staff:** 400+
- **1st Generics Company to be approved for Liraglutide in an ICH or major regulated market**
- **7 Manufacturing sites** (6 in India + 1 in U.S.)
- **90+ cGMP approvals** till date.
- **Key Technologies for APIs:** Fermentation, Chemical Synthesis, Peptide Synthesis and HPAPIs.
- **Key Technologies for Generic Formulations:** Oral Solid Dosage (Potent / Non-Potent), Sterile injectables
- **Approvals from:** U.S. FDA, EMA, MHRA (UK), TGA (Australia), Cofepris (Mexico), ANVISA (Brazil) and MFDS (South Korea)
- **Robust Quality Management Systems**, adherence to GMP and rigorous control and assurance measures.



Balanced Portfolio of Generic APIs, Formulations



APIs	Generic Formulations
Cardiovascular	Cardiovascular (Atorvastatin, Dabigatran etc)
Anti-Diabetics	Anti-diabetic & Anti-obesity (GLP-1s: Liraglutide)
Immunosuppressants	Immunosuppressants (Tacrolimus, Mycophenolic Sodium)
Oncology	Oncology (Everolimus, Lenalidomide, Dasatinib etc)
Blood and Blood forming organs	CNS (Vigabatrin Tablet & Oral Solution)
Multiple Sclerosis	Multiple Sclerosis (Fingolimod)
Anti-Fungal	Anti-Fungal (Posaconazole)

Forward integrating portfolio of niche, difficult-to-make APIs into formulations



Generics Business At A Glance



50+

APIs in portfolio



60+

Generic
Formulations in
portfolio



750+

Pharma companies
served



100+

Countries reached
commercially



7

Manufacturing
sites



90+

cGMP approvals
from international
regulatory agencies



8%

R&D investment as
% of revenue



400+

R&D Staff

Note: Status as of March 2024

Biosimilars Business

End-to-End Capabilities Across the Biosimilars Value Chain



Research & Development



Cutting-edge science & technology capabilities



Manufacturing



State-of-the-art facilities with global-scale capacity



Commercialization



Commercial reach extending across 120+ countries

Setting New Benchmarks in Global Biosimilars Industry



INSULINS

2004

World's 1st *Pichia Pastoris* technology-based **rh-Insulin** developed & commercialized in India



2020

1st company from India to commercialize **bGlargine** in U.S.



2016

1st company from India to have a biosimilar approved in Japan -- **bGlargine**

2021

1st company globally to commercialize **interchangeable bGlargine** in U.S.



mAbs\rPROTEINS

2014

World's 1st **bTrastuzumab** launched in India



2018

1st company globally to get U.S. FDA approval for **bPegfilgrastim**



2017

1st company globally to get U.S. FDA approval for **bTrastuzumab**

2024

1st company to get U.S. FDA approval for **interchangeable bAflibercept**









A Long-standing Presence in the Biosimilars Industry with a Proven Track Record of Global Success



Robust Biosimilars Pipeline Supports Medium-term Growth

Comprehensive Product Portfolio Across Therapy Areas Unlocks a ~US\$100 Bn Global Opportunity

Therapy Area	 Oncology	 Immunology	 Diabetes	 Eye Health	 Bone Health	 Others
Commercial / Approved <i>10 molecules</i>	<ul style="list-style-type: none"> • bPegfilgrastim • bTrastuzumab • bBevacizumab 	<ul style="list-style-type: none"> • bAdalimumab • bEtanercept • bUstekinumab* 	<ul style="list-style-type: none"> • bGlargine U100 • rh-Insulin • bAspart 	bAflibercept		
Late Stage¹ <i>2 assets</i>	<ul style="list-style-type: none"> • bDenosumab • bPertuzumab 				bDenosumab	
Early Stage² <i>8 assets</i>	<ul style="list-style-type: none"> • 2 Undisclosed Assets 	3 undisclosed assets	<ul style="list-style-type: none"> • bGlargine U300 • 1 Undisclosed Asset 			1 Undisclosed Asset

Commercialized in Global Markets

09

20 Biosimilars in our Portfolio

¹ Clinical to BLA Review | ² Pre-Clinical | *Approved in EU, Japan; Launched in U.S.

Fully Integrated, Global-Scale Biologics Production Capacities

- 3 state-of-the-art manufacturing sites for insulins, mAbs & conjugated rProteins (2 India, 1 Malaysia)
- 80+ cGMP approvals from 25+ regulators (including U.S. FDA & EMA)
- Drug Substance, Drug Product & Devices capabilities
- 300+ KL Drug Substance manufacturing capacity across 3 sites
- ~100 million units Drug Product manufacturing capacity across 3 sites
- Stringent Quality & Compliance standards

Certified By:



Center of Excellence for Insulin Production in Johor, Malaysia

- State-of-the-art integrated insulins manufacturing facility set up at an investment of over \$350 million.
- Facility approved by U.S. FDA, EMA, NPRA (Malaysia), TGA (Australia), ANVISA (Brazil), etc.
- Investing an additional \$250 million on Phase 2 of Malaysia facility.
- Recognized as first and largest integrated insulins manufacturer in Malaysia by the prestigious Malaysia Book of Records.



Enabling Insulin Self-sufficiency for Malaysia, Expanding Affordable Access to Lifesaving Insulin Therapy For Patients Worldwide



Strong Commercial Capabilities: Reach in 120+ Countries



Leveraging ‘Lab to Market’ Capabilities to Address Patients’ Needs Across Geographies

Biosimilars Value Chain	Product Development	✓
	Clinical Trials	✓
	Regulatory	✓
	Manufacturing	✓
	Supply Chain	✓
	Commercialization	✓

Pursuing Self-led Commercial Model In 21 Advanced Markets (including U.S., Canada, Germany, France, UK, Spain, Italy) and 8 Emerging Markets





Global Reach in
120+
Countries



Top 5
Global Insulins
Player¹



Top 15
in Global
Biomanufacturing
Capacity²



80+
cGMP Approvals
Received from
Key Regulatory
Agencies



Diverse Global
Talent Pool of
~5,500
People



390+
Patents



Portfolio
Comprises
20 Biosimilars



8
Commercialized
Products in Global
Markets



5+ mn
Patients Served
Annually

Unique, Fully Vertically Integrated Leading Global Biosimilars Player

Research Services Business

A Global CRO and CDMO Offering Integrated Solutions



Innovative R&D, Manufacturing

Service offerings incorporate cutting-edge technologies like CAR-T, mRNA, ADCs, and oligonucleotides

Established track record in discovery research and development for small and large molecules. Emerging presence in commercial manufacturing



Collaborations

Working with 400+ clients, including 14 of the top 20 pharma companies



Strong Technical Expertise

Expertise and capability to deliver great science, ensuring robust data security and high-quality manufacturing, at speed.

Operating in-line with the highest global quality standards across the value chain from R&D to manufacturing

Partnered with Global Leaders in Multiple Industry Segments



Bristol Myers Squibb

GSK

sanofi

NOVARTIS

AMGEN

MERCK

Boehringer
Ingelheim

Baxter



Large & Mid-Sized
BioPharma

Albireo
AN IPSEN COMPANY

AMPHISTA
THERAPEUTICS

Idorsia

Genmab

ASCENEURON
A Neurocryst Therapeutics Company

PharmAust
LIMITED

saniona

C4 Therapeutics



Emerging
BioPharma (EBP)

zoetis

Elanco

MERCK



Animal Health

FMC

DOW
Dow AgroSciences



AgroChem

Givaudan

PURINA

Unilever



CPG

BAUSCH+LOMB

essilor

Beiersdorf

KRATON



Chemicals/
Polymers

Note: Status as of March 2024



2

R&D Centers



400+

Active clients



5600~

Scientists, including
~550 PhDs



390+

Divisions:
Discovery Services
Dedicated R&D Centers
Development Services
Manufacturing Services



400+

Patents assigned
to clients



2 mn sq ft

R&D and
manufacturing
infrastructure

Novel Biologics Business





- Clinical-stage biopharmaceutical company
- Committed to bringing transformative bifunctional therapies for solid tumors
- Lead asset is Ficerafusp alfa (BCA101), a first-in-class, dual-action, bifunctional EGFR/TGF- β antibody
- Bicara starts trading on Nasdaq in September 2024: Raised US\$ 362 million from IPO



Financials



Biocon Group: Financial Highlights for FY24




Rs Million

	YoY	FY 24	FY 23
Revenue	+35%	156,212	115,501
EBITDA	+44%	41,642	28,876
% margin		27%	25%
PBT Before Exceptional Items	+29%	15,368	11,885
PBT	+70%	15,252	8,971
Net Profit	+121%	10,225	4,627

Figures above are rounded off to the nearest million; % based on absolute numbers.

Biocon: Business Revenue Mix FY24



Biocon Limited FY24 Revenues at USD 1.9 billion | Biocon Biologics FY24 Revenues at USD 1.1 billion



Biocon Group: Financial Highlights for 9M FY25



Rs Million

	YoY%	YoY% (Adj.)	9M FY 25	9M FY 24
Revenue	+3%		120,160	116,555
EBITDA	+2%		32,595	31,997
% margin			27%	27%
PBT Before Exceptional Items	+9%		13,238	12,090
PBT	+16%		13,998	12,062

Figures above are rounded off to the nearest million; % based on absolute numbers.

9M FY25 financial performance reflects both continued executional delivery and strategic strengthening across Biocon Group companies

The background image shows a wide body of water, possibly a lake or a large reservoir. In the foreground, there is a floating garden bed with various green plants and small yellow flowers. A blue floating ring is visible on the left side of the water. In the background, a city skyline is visible under a cloudy sky, with several buildings and a construction crane. The entire image has a teal overlay.

Environment, Social, Governance

ESG: Going Beyond Financials to Have a Positive Impact




Our ESG Strategy is Focused on 'Unconditional Equity'



 Improve access to high-quality therapeutics to drive **'Patient Equity'**




 Build an empowering and inclusive workplace creating **'People Equity'**




 Adapting to sustainable business operations for **'Environmental Equity'**



 Operate with integrity, transparency and accountability, ensuring **'Stakeholder Equity'**



 Enable underserved communities for **'Social Equity'**

Monitor Performance → Improve Through Initiatives → Report Outcomes



Successfully Embedding Sustainable Practices Throughout Biocon's Operations



- S&P Global **ESG Score** at **69** vs 63 last year
- **Environmental Dimension**: Score: **76** | Industry max: 76 | Industry mean: 15
- **Social Dimension**: Score: **74** | Industry max: 76 | Industry mean: 23
- **Governance & Economic Dimension**: Score: **62** | Industry max: 70 | Industry mean: 32
- **Biocon Biologics** achieved **ESG Score** of **53** in its S&P Global CSA debut

S&P Global

69/100

Member of

**Dow Jones
Sustainability Indices**

Powered by the S&P Global CSA

Biocon Limited
S&P Global ESG Score 2024



United Nations
Global Compact

Biocon Group is a member of UNGC, the world's largest corporate sustainability initiative
Company incorporating 10 Principles of UNGC into strategies, policies, procedures



ESG Awards & Recognitions



	<p>Included in S&P Global 2024 Sustainability Yearbook 2 years in a row</p>		<p>Enhanced FTSE4GOOD Index score to 3.6 from 3.2, surpassing the healthcare industry average of 2.3 and biotech sub-industry average of 2.8</p>
	<p>Included in DJSI EMs Index for 3 consecutive years</p>		<p>ISS ESG Corporate Score improved to 45.65 vs 41.49</p>
	<p>CDP 2023 scores at 'B' for Climate Change & 'C' for Water Security</p>		<p>Won Excellence in Sustainability Award at the India Pharma Awards organized by Informa Markets India at CPHI India 2024</p>
	<p>Ranked among Top 5 Most Sustainable Companies in Pharma & Healthcare sector at the BW Businessworld Sustainability Awards 2024</p>		<p>Received Silver Medal in EcoVadis 2023 rankings. With a score of 70, Biocon placed in 92nd percentile</p>


Biocon Foundation's Programs Align with Schedule VII CSR Activities as Notified Under Section 135 of the Companies Act 2013



eLAJ Smart Clinics: ~ 65,350+ patient visits (FY24)



Biocon-Hebbagodi Metro Station



Specialist Camps

- NCD Camps
- Geriatric Camps
- Well Baby Camps
- Dental Camps



Expanding Healthcare in Tribal Areas: Providing healthcare access to individuals, screening NCDs.



- A combination of academic and experiential learning
- Scholarship up to 75% on course fee
- **1,000+** students graduated in 10 years
- 100% Placement Record

Education Partners:



Developing high-end talent for the Biotech sector

PROGRAMS


- Biocon-KGI Certificate Program in Biosciences
- BITS Biocon Certificate Program in Applied Industrial Microbiology
- Biocon JSS AHER Certificate Program in Global Regulatory Affairs
- Biocon Ramaiah Certificate Program in Quality Control Analytical
- Syngene Ramaiah Certificate Program in Sterile Manufacturing
- Biocon Academy Certificate Program in Faculty Development
- Biocon KGI Certificate Program in Bioscience Management

People Equity: Ranked Among Top 10 Global Pharma & Biotech Employers



Biocon (including Biocon Biologics) Ranked No. 9 in Top 20

Science 2024 TOP EMPLOYERS



Biocon Has Been On The Top 20 Global Biotech Employers List Since 2012



Note: Science Top Employer is a Top 20 Global Pharma & Biotech Employers annual ranking by the U.S.-based Science magazine

Thank You